logo
Africa Centres for Disease Control and Prevention (Africa CDC) Warns: Millions of African Children Still Lack Access to Life-Saving Vaccines

Africa Centres for Disease Control and Prevention (Africa CDC) Warns: Millions of African Children Still Lack Access to Life-Saving Vaccines

Zawya30-04-2025

Despite the proven power of vaccines to save lives, over 500,000 children under five in Africa continue to die each year from preventable diseases, including measles, diphtheria, tetanus, polio, and whooping cough—diseases that have been nearly eradicated in much of the world.
Providing effective protection against these illnesses should be straightforward, yet across the continent, vaccination remains out of reach for millions. Limited domestic health funding, low trust in vaccines, political instability, and the challenge of accessing remote communities all contribute to the problem.
In 2023, just 16 African countries achieved over 90% coverage for essential childhood vaccines, including the third dose of diphtheria, tetanus, and pertussis (DTP3), and the first dose of the measles-containing vaccine (MCV1). As a result, millions of children remain vulnerable to preventable diseases. A vial of measles vaccine, for instance, costs only USD 2.85. Yet since 2018, 28 African countries have experienced large, disruptive measles outbreaks.
The number of 'zero-dose' children—those who have received no vaccines at all—rose to 7.9 million in 2023, a 16% increase from 2019. These numbers reflect the long-lasting impact of COVID-19, inequities in health access, and system-wide fragilities. Countries like Nigeria, the Democratic Republic of Congo, and South Sudan continue to report high mortality rates from vaccine-preventable diseases due to inconsistent coverage. Recent outbreaks in Somalia, Zimbabwe, Ethiopia, and ongoing cases of diphtheria and pertussis in Chad and Nigeria highlight the scale of the challenge.
Vaccine-preventable diseases cost African countries an estimated USD 13 billion annually, placing additional strain on overstretched health systems and slowing economic progress. Yet immunisation remains one of the most cost-effective health investments, with a return on investment of up to 37 times the cost.
Africa CDC, in collaboration with the African Union Commission (AUC), WHO, UNICEF, GAVI, PATH, and other partners, is advancing the Continental Immunisation Strategy. Guided by the Addis Declaration on Immunisation and aligned with the Immunisation Agenda 2030, this strategy is building a unified, resilient, and equitable immunisation system across the continent.
'Africa currently produces less than 1% of the vaccines it uses. This is a challenge we are committed to changing,' said Dr. Jean Kaseya, Director General of Africa CDC. 'Our goal is to manufacture 60% of vaccines used in Africa locally by 2040.' In 2024 alone, 25 vaccine manufacturing projects were underway on the continent, with eight antigens expected to be WHO prequalified and market-ready between 2025 and 2030.
Africa CDC continues to strengthen cold chain systems, train health workers, improve data and pharmacovigilance, and mobilise vaccines for emergencies such as COVID-19 and mpox. It is also leading efforts to boost domestic resource mobilisation and develop innovative financing approaches to close persistent immunisation gaps.
Africa Vaccination Week is a timely reminder that while the challenges are immense, the solutions are within reach. With renewed investment, strong political will, and regional coordination, Africa can protect its children and build a healthier, more resilient future.
Distributed by APO Group on behalf of Africa Centres for Disease Control and Prevention (Africa CDC).

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Angola takes a decisive step towards ensuring safer, more effective, and more accessible medicines and health technologies
Angola takes a decisive step towards ensuring safer, more effective, and more accessible medicines and health technologies

Zawya

time18 hours ago

  • Zawya

Angola takes a decisive step towards ensuring safer, more effective, and more accessible medicines and health technologies

Between June 3 and 5, the Angola Medicines and Health Technologies Regulatory Agency (ARMED), with technical support from World Health Organization (WHO) and funding from the European Union (EU), held a strategic meeting to monitor progress in implementing the recommendations made as part of the assessment of its regulatory maturity. The session was attended by 25 ARMED professionals and resulted in the drafting of the Institutional Development Plan (IDP), the aim of which is to strengthen the national regulatory system, bringing it into line with international standards, in a context in which the pharmaceutical sector is becoming increasingly attractive for investment. According to WHO Representative in Angola, Dr. Indrajit Hazarika, supervision is an essential pillar of the pharmaceutical sector, encompassing a complex network of production, distribution, and marketing medicines. Dr. Hazarika stressed that 'medicines and medical products are fundamental for access to health care, and it is essential to guarantee their quality so that the goal of health for all can be achieved'. This meeting is part of WHO's ongoing support to the Angolan government in strengthening the regulatory system. WHO experts from the Geneva headquarters and the Africa regional and national offices analyzed the Angolan regulatory system based on WHO Quality Management System principles and the international benchmarking tool - the Global Benchmarking Tool (GBT). During the meeting, the progress made in implementing the technical recommendations was assessed, and a review was also made of the actions taken following the 2022 and February 2024 self-assessment exercises. The Institutional Development Plan (IDP) was updated in this context, a strategic document that will guide ARMED until 2027. The aim is to reach Maturity Level 3, internationally recognized as the benchmark for a functional regulatory system, capable of guaranteeing the availability of safe, effective, and quality medicines on the national market. Despite the progress already made, the pace of implementation needs to be accelerated. Holding regular meetings to follow up on the IDP is key to monitoring progress, identifying obstacles, adjusting strategies, and ensuring continued alignment with international standards. In addition, these meetings also strengthen institutional commitment, promote transparency, and facilitate coordination between technical and financial partners. ARMED's Director General, Dr. Pombal Mayembe, stressed the importance of the initiative. 'At the World Health Assembly, there was extensive discussion about the local production of medicines. Angola cannot be left out of this movement. We want to reach level 3 of maturity by 2027. Is that possible? Yes, with the support of WHO, EU, and other partners, we are firmly committed to achieving this goal.' For his part, Pierre Destexhe, representing the European Union, highlighted ARMED's role in controlling the quality of the national medicines market, as well as its contribution to ensuring that access to safe, quality medicines becomes an ever greater reality in Angola, within the scope of Universal Health Coverage. The meeting, which made it possible to assess progress and draw up ARMED's IDP, represents a decisive step towards consolidating a robust regulatory system in Angola, reaffirming the government's commitment to guaranteeing the population's access to safe, quality medicines, while at the same time promoting local production based on international standards. Distributed by APO Group on behalf of World Health Organization (WHO) - Angola.

MediLink Therapeutics Taps Major Banks for Hong Kong Float
MediLink Therapeutics Taps Major Banks for Hong Kong Float

Arabian Post

timea day ago

  • Arabian Post

MediLink Therapeutics Taps Major Banks for Hong Kong Float

MediLink Therapeutics Ltd. is preparing to launch an initial public offering in Hong Kong, having secured China International Capital Corp., JPMorgan Chase & Co. and Morgan Stanley as its lead advisers, according to people with knowledge of the matter. The move comes as the clinical-stage biotech firm seeks to capitalise on growing investor interest in advanced tumour-targeting therapies and consolidate its platform of antibody‑drug conjugates. Founded in 2020 and headquartered in Suzhou with R&D operations in Shanghai and Boston, MediLink has developed a proprietary ADC technology known as TMALIN®. The platform facilitates precise delivery of cytotoxic agents to tumour cells, with the intention of widening therapeutic windows for solid tumour treatments. Its pipeline includes programs that have advanced to clinical stages in both China and the United States, supported by a Series B financing round of approximately USD 70 million in 2022. MediLink's strategic engagement of three underwriters reflects heightened confidence in anchor investors and broader syndication. China International Capital Corp. brings deep roots in Chinese capital markets and extensive IPO experience in the biotech sector. JPMorgan and Morgan Stanley add global banking heft and access to international investors. ADVERTISEMENT CICC itself is emerging as a top-tier sponsor for Hong Kong listings. It led or co-led 19 IPOs for Chinese corporates last year, raising USD 3.84 billion, positioning it as a dominant force amid market revival. The engagement of internationally renowned banks alongside CICC is likely aimed at boosting MediLink's valuation and widening investor interest both locally and abroad. While IPO details remain confidential, analysts suggest MediLink could seek a valuation in the mid‑to‑high hundreds of millions of dollars. That would reflect both the advanced stage of its pipeline and prevailing market multiples for ADC developers. Comparable biotech flotations in Hong Kong and the U.S. have reflected growing appetite for oncology-focused platforms. Alongside listing ambitions, MediLink continues to advance its clinical and licensing goals. In March it unveiled preclinical data at the American Association for Cancer Research annual meeting; earlier in the year it received FDA clearance for its IND application for YL217, its lead candidate. YL201, another programme, received Breakthrough Therapy Designation in January for treatment of recurrent/metastatic nasopharyngeal carcinoma. The company has also pursued strategic licensing agreements with global pharmaceutical firms to expand development and commercialisation capabilities. A licensing deal under discussion ahead of the IPO is believed aimed at enhancing distribution reach while reinforcing MediLink's balance sheet. The IPO effort is part of a broader resurgence in biotech listings in Hong Kong, where authorities have eased regulations to attract innovation-driven offerings. CICC and other banks have ramped up support for ADC and gene therapy companies, signalling a turning point after a lull in listings. ADVERTISEMENT MediLink's choice of banks aligns with a wider trend: CICC has co-sponsored blockbuster floats including the forthcoming mega‑IPO of CATL, while banks like Goldman Sachs and Morgan Stanley have also participated. In this context, MediLink is positioning itself to tap both deep domestic networks and international capital. Stakeholder sentiment appears optimistic. MediLink's management team, comprised of co‑founders Tony Xue and Jiaqiang Cai alongside C‑suite leaders experienced in drug development and financial strategy, has overseen steady progress in its ADC pipeline and established global partnerships. Jason Li's appointment as CFO in 2023 reportedly strengthened the company's capital market readiness. Market observers highlight challenges ahead. ADC development remains capital-intensive, clinical risks high, and competition fierce among domestic and international peers. Success will hinge on late‑stage data and licensing traction. At the same time, geopolitical tensions and volatility in Hong Kong equity markets may affect investor sentiment. MediLink must also navigate post‑IPO obligations, including regulatory reporting and corporate governance under Hong Kong's Main Board requirements. Mitigating execution risk will be critical, underscoring the role of its chosen bankers in underwriting diligence and market support. Analysts describe the listing as a pivotal moment: it offers the backing to fund Phase II/III efforts while elevating MediLink's corporate profile. For banks, it reinforces Hong Kong's appeal as a biotech capital market when compared with established centres like Nasdaq. With its IPO process underway, MediLink now awaits market timing and regulatory clearances before formally filing a prospectus. The company is expected to continue advancing clinical data, strengthening licensing ties, and preparing investor materials aligned with regulatory requirements.

The World Health Organization (WHO) Donates Mobile Water Testing Kits to Boost Angola's Water Safety Monitoring
The World Health Organization (WHO) Donates Mobile Water Testing Kits to Boost Angola's Water Safety Monitoring

Zawya

time2 days ago

  • Zawya

The World Health Organization (WHO) Donates Mobile Water Testing Kits to Boost Angola's Water Safety Monitoring

The World Health Organization (WHO) today donated three mobile water quality testing kits to the Ministry of Health, through the Instituto Nacional de Investigação em Saúde (INIS), to strengthen Angola's capacity to monitor and respond to waterborne disease risks—especially during health emergencies such as the ongoing cholera outbreak. These mobile kits allow for on-the-spot analysis of water sources, enabling health teams to detect issues such as pH levels, chlorine concentration, turbidity, and other key indicators of water safety—without the delays caused by transporting samples to laboratories. 'In provinces like Lunda Norte, we've faced serious challenges collecting and transporting water samples from remote communities,' said Alex Freeman, a WASH and Health logistics specialist deployed to Angola with the support of the WHO Nairobi AFRO Emergency Hub 'Now, with these mobile kits, we can conduct accurate tests immediately at the point of collection, enabling faster decision-making and a more agile public health response.' As part of the rollout, nine INIS staff members were trained on the use of the mobile kits, with additional training planned for personnel from other sectors in the coming weeks. The testing kits are also a practical tool for routine monitoring in hospital settings, helping ensure safe water for patients and health workers. As part of WHO's mandate to support water quality surveillance, the kits represent an important operational boost for both preventive health efforts and outbreak response. 'This is a great example of collaboration and targeted support,' said Simão Nhassengo, a WASH specialist deployed to Angola with the support of the government of the Netherlands. 'These kits will play an important role in monitoring water safety across Angola and ultimately help prevent the spread of waterborne diseases like cholera.' The initiative was made possible thanks to the generous contributions of the European Union through European Civil Protection and Humanitarian Aid Operations (ECHO), and the Embassy of the Netherlands, whose support has also enabled technical deployments to strengthen water, sanitation, and hygiene (WASH) capacity across the country. Distributed by APO Group on behalf of World Health Organization (WHO) - Angola.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store